Jianjun Gao

26PUBLICATIONS
293CO-AUTHORS
Molecular targetsSolid tumoursCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Aug 21, 2026
Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity.

|May 28, 2026
Pan-cancer spatial atlas of tertiary lymphoid structures.

|May 13, 2026
A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture.

|Apr 20, 2026
Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma.

|Nov 25, 2025
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence.

Melinda Soeung, Xinmiao Yan, Ciro Zanca

|Aug 01, 2025
Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities.

Anne Knisely, Yibo Dai, Graham L Barlow

Pageof 5

Frequent Collaborators

14 joint publications

Linghua Wang

12 joint publications

Pavlos Msaouel

9 joint publications

Andrew Futreal

8 joint publications

Matthew T Campbell